Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $1.28. Regulus Therapeutics shares last traded at $1.26, with a volume of 2,486,923 shares changing hands.
Several equities analysts have recently commented on the company. HC Wainwright increased their price objective on Regulus Therapeutics from $1.50 to $2.00 and gave the company a “buy” rating in a research report on Friday, May 14th. Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 12th.
The stock has a market cap of $78.67 million, a PE ratio of -2.76 and a beta of 2.32. The firm’s 50-day moving average price is $1.17.
Hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC purchased a new stake in Regulus Therapeutics during the 1st quarter valued at about $31,000. Focused Wealth Management Inc purchased a new stake in Regulus Therapeutics during the 1st quarter valued at about $156,000. Northern Trust Corp boosted its holdings in Regulus Therapeutics by 198.4% during the 1st quarter. Northern Trust Corp now owns 117,654 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 78,223 shares during the period. Squarepoint Ops LLC boosted its holdings in Regulus Therapeutics by 1,477.7% during the 1st quarter. Squarepoint Ops LLC now owns 159,804 shares of the biopharmaceutical company’s stock valued at $249,000 after acquiring an additional 149,675 shares during the period. Finally, Morgan Stanley lifted its holdings in Regulus Therapeutics by 2,799.7% in the 1st quarter. Morgan Stanley now owns 163,251 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 157,621 shares during the period. Institutional investors own 36.44% of the company’s stock.
Regulus Therapeutics Company Profile (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.